Clinical pharmacology quality assurance program: Models for longitudinal analysis of antiretroviral proficiency testing for international laboratories

Therapeutic Drug Monitoring

Volumn 35, Issue 5, 2013, Pages 631-642

  Difrancesco, Robin ^a   Rosenkranz, Susan L ^b   Taylor, Charlene R ^a   Pande, Poonam G ^c   Siminski, Suzanne M ^b   Jenny, Richard W ^d   Morse, Gene D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^c RTI INTERNATIONAL   (United States)

^d NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

antiretroviral proficiency testing; interlaboratory performance; longitudinal analysis model

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ACCURACY; ANALYTICAL ERROR; ARTICLE; CLINICAL ASSESSMENT; CLINICAL LABORATORY; CLINICAL LABORATORY IMPROVEMENT ACT; CLINICAL PHARMACOLOGY; CLINICAL PHARMACOLOGY LABORATORY; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; DRUG SCREENING; GOOD LABORATORY PRACTICE; HEALTH CARE POLICY; HUMAN; LABORATORY TEST; LONGITUDINAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHARMACOGENOMICS; PRIORITY JOURNAL; QUALITY CONTROL; STATISTICAL MODEL;

ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS; LABORATORIES; LABORATORY PROFICIENCY TESTING; LONGITUDINAL STUDIES; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL; QUALITY CONTROL; RESEARCH DESIGN;

EID: 84884999892     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31828f5088     Document Type: Article

References (15)

1. Miller WG, Jones GR, Horowitz GL, et al. Proficiency testing/external quality assessment: Current challenges and future directions. Clin Chem. 2011;57:1670-1680
2. Droste JA, Koopmans PP, Hekster YA, et al. TDM: Therapeutic drug measuring or therapeutic drug monitoring? Ther Drug Monit. 2005;27: 412-416
3. Aarnoutse RE, Schapiro JM, Boucher CA, et al. Therapeutic drug monitoring: An aid to optimising response to antiretroviral drugs? Drugs. 2003;63:741-753
4. Aarnoutse RE, Verweij-van Wissen CP, van Ewijk-Beneken Kolmer EW, et al. International interlaboratory quality control program for measurement of antiretroviral drugs in plasma. Antimicrob Agents Chemother. 2002;46:884-886
5. Droste JA, Aarnoutse RE, Koopmans PP, et al. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr. 2003;32:287-291
6. Burger D, Teulen M, Eerland J, et al. The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: A global proficiency testing program. Ther Drug Monit. 2011; 33:239-243
7. Brüggemann RJ, Touw DJ, Aarnoutse RE, et al. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother. 2009;53: 303-305
8. Holland DT, DiFrancesco R, Stone J, et al. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004;48:824-831
9. Holland DT, DiFrancesco R, Connor JD, et al. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: A requirement for therapeutic drug monitoring. Ther Drug Monit. 2006;28:367-374
10. Steele BW, Wang E, Palomaki GE, et al. An evaluation of analytical goals for assays of drugs. Arch Pathol Lab Med. 2001;125:729-735
11. Carey RN, Cembrowski GS, Garber CC, et al. Performance characteristics of several rules for self-interpretation of proficiency testing data. Arch Pathol Lab Med. 2005;129:997-1003
12. Cembrowski GS, Hackney JR, Carey N. The detection of problem analytes in a single proficiency test challenge in the absence of the Health Care Financing Administration rule violations. Arch Pathol Lab Med. 1993;17:437-443
13. Medicare, Medicaid and CLIA programs; regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Fed Regist. 1992;57:7002-7186
14. Jenny RW, Jackson-Tarentino KY. Causes of unsatisfactory performance in proficiency testing. Clin Chem. 2000;46:89-99
15. VQA Proficiency Testing Scoring Document for Quantitative HIV-1 RNA. HANC HIV/AIDS Network Coordination Web site. Available at: Https://www.hanc.info/ labs/labresources/vqaResources/ptProgram. Accessed December 4, 2012